title: Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas.
abstract: We have found that the use of levonorgestrel-releasing IUS results in a remarkable decrease in endometrial proliferation and a remarkable increase in apoptosis in the endometrium; therefore, it is effective for long-term management of menorrhagic women with uterine myomas because of the striking reduction in menorrhagia. This prompted us to characterize the effects of progesterone (P(4)) and progesterone receptor modulator (PRM) CDB2914 on uterine myoma growth. In vitro studies with cultured uterine leiomyoma cells and normal myometrial cells revealed that P(4) stimulated the proliferative activity in leiomyoma cells, but not in normal myometrial cells. P(4) increased EGF expression, whereas E(2) augmented EGF-R expression in leiomyoma cells, indicating that P(4) and E(2) act in combination to stimulate leiomyoma cell growth. P(4) also increased Bcl-2 expression and decreased TNF-alpha expression in those cells. Unlike the EGF expression, IGF-I expression in leiomyoma cells was inhibited by P(4). These results suggest that P(4) has dual actions on leiomyoma growth: one is to stimulate the growth through up-regulating EGF and Bcl-2 expression, and the other is to inhibit the growth through down-regulating IGF-I expression in the cells. By contrast, CDB2914 inhibited proliferation and stimulated apoptosis of leiomyoma cells without affecting normal myometrial cells. Furthermore, CDB2914 inhibited vascular endothelial growth factor and adrenomedullin expression in leiomyoma cells, but not in normal myometrial cells. The cell type-specific action of CDB2914 on leiomyoma cells, without affecting the surrounding normal myometrial cells, is meaningful for understanding the usefulness of CDB2914 in the medical treatment of uterine myomas.
authors.affiliation: Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe, 650-0017, Japan. maruo@kobe-u.ac.jp
authors.forename: Takeshi
authors.initials: T
authors.lastname: Maruo
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Ohara
authors.forename: Hiroya
authors.initials: H
authors.lastname: Matsuo
authors.forename: Qin
authors.initials: Q
authors.lastname: Xu
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Regine
authors.initials: R
authors.lastname: Sitruk-Ware
authors.forename: Elof D B
authors.initials: ED
authors.lastname: Johansson
mesh_terms: D003271:Contraceptive Agents, Female / Q000494:pharmacology; D004717:Endometrium / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated; D007889:Leiomyoma / Q000188:drug therapy* / Q000378:metabolism; D016912:Levonorgestrel / Q000494:pharmacology; D009649:Norpregnadienes / Q000494:pharmacology*; D011374:Progesterone / Q000378:metabolism; D011980:Receptors, Progesterone / Q000187:drug effects; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D003271:Contraceptive Agents, Female; D009649:Norpregnadienes; D011980:Receptors, Progesterone; D011374:Progesterone; D016912:Levonorgestrel; C094854:ulipristal